KaloBios Pharmaceuticals Shares Outstanding 2011-2021 | HGEN

KaloBios Pharmaceuticals shares outstanding from 2011 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
KaloBios Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 37
2019 22
2018 19
2017 3
2016 2
2015 1
2014 1
2013 1
2012 0
2011 0
2010 0
KaloBios Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 59
2021-03-31 53
2020-12-31 37
2020-09-30 43
2020-06-30 30
2020-03-31 23
2019-12-31 22
2019-09-30 23
2019-06-30 22
2019-03-31 22
2018-12-31 19
2018-09-30 22
2018-06-30 22
2018-03-31 10
2017-12-31 3
2017-09-30 3
2017-06-30 3
2017-03-31 3
2016-12-31 2
2016-09-30 3
2016-06-30 1
2016-03-31 1
2015-12-31 1
2015-09-30 1
2015-06-30 1
2015-03-31 1
2014-12-31 1
2014-09-30 1
2014-06-30 1
2014-03-31 1
2013-12-31 1
2013-09-30 1
2013-06-30 1
2013-03-31 0
2012-12-31 0
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.378B $0.000B
Humanigen, Inc. is a biopharmaceutical company. It focuses on advancing medicines for patients with neglected and rare diseases. The Company's product candidate principally consists of benznidazole, lenzilumab and ifabotuzumab. Humanigen Inc., formerly known as KaloBios Pharmaceuticals Inc., is based in Brisbane, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29